<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunosuppressive therapies have proven valuable in treating patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the combination of equine anti-thymocyte globulin (ATGAM) and the soluble <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor receptor, etanercept (Enbrel), in a phase II trial </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-five patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> [4-refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA), 2-RA with ring sideroblasts, 15-refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>), 3-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> and ring sideroblasts, 1-RA with excess blasts type 1] in International Prognostic Staging System risk groups low (n = 11) or intermediate-1 (n = 14) were enrolled </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were platelet or red cell transfusion-dependent </plain></SENT>
<SENT sid="4" pm="."><plain>Nineteen patients completed therapy with ATG at 40 mg/kg per day for four consecutive days, followed by etanercept, 25 mg subcutaneous twice a week for 2 weeks, every month for 4 months </plain></SENT>
<SENT sid="5" pm="."><plain>Thirteen patients had haematological improvement (HI)-erythroid, 2 HI-neutrophil, and 6 HI-platelet </plain></SENT>
<SENT sid="6" pm="."><plain>One patient with a co-existing diagnosis of multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> and <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> had a complete remission </plain></SENT>
<SENT sid="7" pm="."><plain>The overall response by intent to treat analysis among the 25 patients was 56% (95% confidence interval 35-56%) </plain></SENT>
<SENT sid="8" pm="."><plain>Four patients did not complete their first course of therapy and one patient did not survive to the 8-week post-treatment assessment </plain></SENT>
<SENT sid="9" pm="."><plain>Among patients who completed treatment and survived to the 8-week assessment, 70% had at least haematological responses lasting for at least 5 to more than 36 months </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, combination therapy with ATG and etanercept was active and safe in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>